A condition characterized by calcification of the renal tissue itself. It is usually seen in distal RENAL TUBULAR ACIDOSIS with calcium deposition in the DISTAL KIDNEY TUBULES and the surrounding interstitium. Nephrocalcinosis causes RENAL INSUFFICIENCY.
Excretion of abnormally high level of CALCIUM in the URINE, greater than 4 mg/kg/day.
Genetic defects in the selective or non-selective transport functions of the KIDNEY TUBULES.
A large family of transmembrane proteins found in TIGHT JUNCTIONS. They take part in the formation of paracellular barriers and pores that regulate paracellular permeability.
Excretion of an excessive amount of OXALATES in the urine.
A non-hereditary KIDNEY disorder characterized by the abnormally dilated (ECTASIA) medullary and inner papillary portions of the collecting ducts. These collecting ducts usually contain CYSTS or DIVERTICULA filled with jelly-like material or small calculi (KIDNEY STONES) leading to infections or obstruction. It should be distinguished from congenital or hereditary POLYCYSTIC KIDNEY DISEASES.
A group of genetic disorders of the KIDNEY TUBULES characterized by the accumulation of metabolically produced acids with elevated plasma chloride, hyperchloremic metabolic ACIDOSIS. Defective renal acidification of URINE (proximal tubules) or low renal acid excretion (distal tubules) can lead to complications such as HYPOKALEMIA, hypercalcinuria with NEPHROLITHIASIS and NEPHROCALCINOSIS, and RICKETS.
Stones in the KIDNEY, usually formed in the urine-collecting area of the kidney (KIDNEY PELVIS). Their sizes vary and most contains CALCIUM OXALATE.
An inherited condition of abnormally low serum levels of PHOSPHATES (below 1 mg/liter) which can occur in a number of genetic diseases with defective reabsorption of inorganic phosphorus by the PROXIMAL RENAL TUBULES. This leads to phosphaturia, HYPOPHOSPHATEMIA, and disturbances of cellular and organ functions such as those in X-LINKED HYPOPHOSPHATEMIC RICKETS; OSTEOMALACIA; and FANCONI SYNDROME.
A group of disorders caused by defective salt reabsorption in the ascending LOOP OF HENLE. It is characterized by severe salt-wasting, HYPOKALEMIA; HYPERCALCIURIA; metabolic ALKALOSIS, and hyper-reninemic HYPERALDOSTERONISM without HYPERTENSION. There are several subtypes including ones due to mutations in the renal specific SODIUM-POTASSIUM-CHLORIDE SYMPORTERS.
A genetic disorder characterized by excretion of large amounts of OXALATES in urine; NEPHROLITHIASIS; NEPHROCALCINOSIS; early onset of RENAL FAILURE; and often a generalized deposit of CALCIUM OXALATE. There are subtypes classified by the enzyme defects in glyoxylate metabolism.
Formation of stones in the KIDNEY.
A nutritional condition produced by a deficiency of magnesium in the diet, characterized by anorexia, nausea, vomiting, lethargy, and weakness. Symptoms are paresthesias, muscle cramps, irritability, decreased attention span, and mental confusion, possibly requiring months to appear. Deficiency of body magnesium can exist even when serum values are normal. In addition, magnesium deficiency may be organ-selective, since certain tissues become deficient before others. (Harrison's Principles of Internal Medicine, 12th ed, p1936)
A non-metal element that has the atomic symbol P, atomic number 15, and atomic weight 31. It is an essential element that takes part in a broad variety of biochemical reactions.
A clinically and genetically heterogeneous group of hereditary conditions characterized by malformed DENTAL ENAMEL, usually involving DENTAL ENAMEL HYPOPLASIA and/or TOOTH HYPOMINERALIZATION.
The calcium salt of oxalic acid, occurring in the urine as crystals and in certain calculi.
A hereditary or acquired form of generalized dysfunction of the PROXIMAL KIDNEY TUBULE without primary involvement of the KIDNEY GLOMERULUS. It is usually characterized by the tubular wasting of nutrients and salts (GLUCOSE; AMINO ACIDS; PHOSPHATES; and BICARBONATES) resulting in HYPOKALEMIA; ACIDOSIS; HYPERCALCIURIA; and PROTEINURIA.
Inorganic salts of phosphoric acid.
Formation of stones in any part of the URINARY TRACT, usually in the KIDNEY; URINARY BLADDER; or the URETER.
Body organ that filters blood for the secretion of URINE and that regulates ion concentrations.
An inherited renal disorder characterized by defective NaCl reabsorption in the convoluted DISTAL KIDNEY TUBULE leading to HYPOKALEMIA. In contrast with BARTTER SYNDROME, Gitelman syndrome includes hypomagnesemia and normocalcemic hypocalciuria, and is caused by mutations in the thiazide-sensitive SODIUM-POTASSIUM-CHLORIDE SYMPORTERS.
Disturbances in the body's WATER-ELECTROLYTE BALANCE.
Derivatives of OXALIC ACID. Included under this heading are a broad variety of acid forms, salts, esters, and amides that are derived from the ethanedioic acid structure.
A hereditary disorder characterized by HYPOPHOSPHATEMIA; RICKETS; OSTEOMALACIA; renal defects in phosphate reabsorption and vitamin D metabolism; and growth retardation. Autosomal and X-linked dominant and recessive variants have been reported.
Phosphorus used in foods or obtained from food. This element is a major intracellular component which plays an important role in many biochemical pathways relating to normal physiological functions. High concentrations of dietary phosphorus can cause nephrocalcinosis which is associated with impaired kidney function. Low concentrations of dietary phosphorus cause an increase in calcitriol in the blood and osteoporosis.
A non-electrogenic sodium-dependent phosphate transporter. It is found primarily in apical membranes of PROXIMAL RENAL TUBULES.
Disorders in the processing of calcium in the body: its absorption, transport, storage, and utilization.
A condition caused by a deficiency of PARATHYROID HORMONE (or PTH). It is characterized by HYPOCALCEMIA and hyperphosphatemia. Hypocalcemia leads to TETANY. The acquired form is due to removal or injuries to the PARATHYROID GLANDS. The congenital form is due to mutations of genes, such as TBX1; (see DIGEORGE SYNDROME); CASR encoding CALCIUM-SENSING RECEPTOR; or PTH encoding parathyroid hormone.
The internal portion of the kidney, consisting of striated conical masses, the renal pyramids, whose bases are adjacent to the cortex and whose apices form prominent papillae projecting into the lumen of the minor calyces.
A basic element found in nearly all organized tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes.

Renal biopsy in the milk-alkali syndrome. (1/173)

In milk-alkali syndrome the degree of renal impairment varies greatly. Few reports have been published describing structural changes on renal biopsy. In three illustrative cases, impairment of renal function was related to morphological changes shown on percutaneous biopsy. Milk-alkali syndrome should be considered as a cause of renal dysfunction in patients with a long history of dyspensia.  (+info)

Differential effects of T- and L-type calcium antagonists on glomerular dynamics in spontaneously hypertensive rats. (2/173)

To determine whether there is a difference in the effects of T- and L-type calcium antagonists on systemic, renal, and glomerular hemodynamics, the pathological changes of N(G)-nitro-L-arginine methyl ester (L-NAME)-exacerbated nephrosclerosis and clinical alterations were investigated in spontaneously hypertensive rats (SHR). Seven groups of 17-week-old male SHRs were studied: Group 1, control; Group 2, mibefradil, 50 mg. kg(-1). d(-1); Group 3, L-NAME in drinking water, 50 mg/L; Group 4, L-NAME (50 mg/L) plus mibefradil (50 mg. kg(-1). d(-1)); Group 5, L-NAME (50 mg/L) plus amlodipine (10 mg. kg(-1). d(-1)); Group 6 and 7, L-NAME (50 mg/L) for 3 weeks followed by mibefradil (50 mg. kg(-1). d(-1)) or amlodipine (10 mg. kg(-1). d(-1)), respectively, for the subsequent 3 weeks. Both the T- and L-channel calcium antagonists similarly reduced mean arterial pressure and total peripheral resistance index. These changes were associated with significant decreases in afferent and efferent glomerular arteriolar resistances and the ultrafiltration coefficient (P<0.01). Furthermore, the histopathological glomerular and arterial injury scores and urinary protein excretion were also significantly improved (P<0.01), and left ventricular and aortic masses were significantly diminished in all treated groups. Both drugs, mibefradil and amlodipine, had effects of increasing the single-nephron glomerular filtration ratio (SNGFR), and single-nephron plasma flow (SNPF), and of reducing glomerular afferent arteriolar resistance and urinary protein excretion. Thus, the T-type (mibefradil) and L-type (amlodipine) calcium antagonists each prevented and reversed the pathophysiological alterations of L-NAME-exacerbated hypertensive nephrosclerosis in SHR. The T-type calcium antagonist (mibefradil) seemed to have been more effective than the L-type amlodipine antagonist and it produced a greater reduction in afferent arteriolar resistance while preserving SNGFR.  (+info)

Vitamin D3-induced proliferative lesions in the rat adrenal medulla. (3/173)

Adrenal medullary hyperplasia and pheochromocytomas are induced in rats by a variety of non-genotoxic agents, and we have hypothesized that these agents induce lesions indirectly by stimulating chromaffin cell proliferation. Vitamin D3, which has not been previously associated with adrenal medullary proliferative lesions, is the most potent in vivo stimulus to chromaffin cell proliferation yet identified. The present investigation utilized the vitamin D3 model to prospectively test the relationship between mitogenicity and focal proliferative lesions in the adrenal medulla and to determine early events in the pathogenesis of these lesions. Charles River Crl:CD BR rats were treated with 0; 5000; 10,000; or 20,000 IU/kg/day of vitamin D3 in corn oil (5 ml/kg) by oral intubation. Rats were killed after 4, 8, 12, or 26 weeks of treatment, following a final week of labeling with bromodeoxyuridine (BrdU) using a mini-pump. Adrenal sections were double-stained for BrdU and phenylethanolamine-N-methyl transferase (PNMT) to discriminate epinephrine (E) from norepinephrine (NE) cells or for vesicular acetylcholine transporter (VAchT) to identify cholinergic nerve endings. Vitamin D3 caused a 4-5-fold increase in BrdU labeling at week 4, diminishing to a 2-fold increase by week 26. An initial preponderance of labeled E cells gave way to a preponderance of labeled NE cells. By week 26, 17/19 (89%) animals receiving the 2 highest doses of vitamin D3 had focal adrenal medullary proliferative lesions, in contrast to an absence of lesions in control rats. The lesions encompassed a spectrum including BrdU-labeled "hot spots" not readily visible on H and E sections, hyperplastic nodules, and pheochromocytomas. Lesions were usually multicentric, bilateral, and peripheral in location, and almost all were PNMT-negative. The lesions were not cholinergically innervated, suggesting autonomous proliferation. Hot spots, hyperplastic nodules, and pheochromocytomas appear to represent a continuum rather than separate entities. Their development might involve selective responses of chromaffin cell subsets to mitogenic signals, influenced by both innervation and corticomedullary interactions. A number of non-genotoxic compounds that induce pheochromocytomas in rats are known to affect calcium homeostasis. The results of this study provide further evidence to support the hypothesis that altered calcium homeostasis is indirectly involved in the pathogenesis of pheochromocytomas, via effects on chromaffin cell proliferation.  (+info)

Effects of low animal protein or high-fiber diets on urine composition in calcium nephrolithiasis. (4/173)

BACKGROUND: The purpose of this article is to evaluate the impact of low protein and high fiber intakes on risk factors of stone recurrence in idiopathic calcium stone formers (ICSFs). METHODS: Ninety-six ICSFs were randomly assigned a low animal protein diet (< 10% of total energy), a high-fiber diet (> 25 g/day), or a usual diet (control group); all patients were recommended to increase their fluid intake. Their daily urine compositions were analyzed at baseline and at four months. Compliance with dietary recommendations was checked by validated food frequency questionnaires. Compliance with total and animal protein intakes was assessed by 24-hour urea and sulfate outputs, respectively. The nutritional intervention (oral instructions, written leaflet, phoning) and food assessment were carried out by a research dietitian. RESULTS: At baseline, diets and the daily urine composition did not differ between the three groups. At four months, while diets differed significantly, the 24-hour output of calcium and oxalate did not differ significantly within and between groups after adjustment for potential confounders (age, sex, and personal and family history of calcium stones) and baseline values. However, as many as 12 out of 31 ICSFs (95% CI, 22 to 58%) assigned to a low animal protein diet achieved a reduction in the urine urea excretion rate of more than 50 mmol/day and also exhibited a significant decrease in urinary calcium excretion that averaged 1.8 mmol/day. A significant correlation between urea and calcium outputs was observed only among patients with hypercalciuria. CONCLUSIONS: These results show that only ICSFs who markedly decrease their animal protein intake, especially those with hypercalciuria, can expect to benefit from dietary recommendations.  (+info)

Urinary oxalate excretion in urolithiasis and nephrocalcinosis. (5/173)

AIMS: To investigate urinary oxalate excretion in children with urolithiasis and/or nephrocalcinosis and to classify hyperoxaluria (HyOx). METHODS: A total of 106 patients were screened. In those in whom the oxalate: creatinine ratio was increased, 24 hour urinary oxalate excretion was measured. Liver biopsy and/or genomic analysis was performed if primary hyperoxaluria (PH) was suspected. Stool specimens were examined for Oxalobacter formigenes in HyOx not related to PH type 1 or 2 (PH1, PH2) and in controls. RESULTS: A total of 21 patients screened had HyOx (>0.5 mmol/24 h per 1.73 m(2)); they were classified into five groups. Eleven had PH (PH1 in nine and neither PH1 nor PH2 in two). Six had secondary HyOx: two enteric and four dietary. Four could not be classified. Seven patients had concomitant hypercalciuria. Only one of 12 patients was colonised with O formigenes compared to six of 13 controls. CONCLUSIONS: HyOx is an important risk factor for urolithiasis and nephrocalcinosis in children, and can coexist with hypercalciuria. A novel type of PH is proposed. Absence of O formigenes may contribute to HyOx not related to PH1.  (+info)

Hypomagnesaemia-hypercalciuria-nephrocalcinosis: a report of nine cases and a review. (6/173)

BACKGROUND: The cardinal characteristics of primary hypomagnesaemia-hypercalciuria-nephrocalcinosis include renal magnesium wasting, marked hypercalciuria, renal stones, nephrocalcinosis, a tendency towards chronic renal insufficiency and sometimes even ocular abnormalities or hearing impairment. METHODS: As very few patients with this syndrome have been described, we provide information on nine patients on follow-up at our institutions and review the 42 cases reported in the literature (33 females and 18 males). RESULTS: Urinary tract infections, polyuria-polydipsia, renal stones and tetanic convulsions were the main clinical findings at diagnosis. The clinical course was highly variable; renal failure was often reported. The concomitant occurrence of ocular involvement or hearing impairment was reported in a large subset of patients. Parental consanguinity was noted in some families. CONCLUSIONS: The results indicate an autosomal recessive inheritance. The diagnosis of primary hypomagnesaemia-hypercalciuria-nephrocalcinosis deserves consideration in any patient with nephrocalcinosis and hypercalciuria.  (+info)

Familial hypomagnesaemia with hypercalciuria and nephrocalcinosis maps to chromosome 3q27 and is associated with mutations in the PCLN-1 gene. (7/173)

Familial hypomagnesaemia with hypercalciuria and nephrocalcinosis (FHHNC, MIM 248250) is a complex renal tubular disorder characterised by hypomagnesaemia, hypercalciuria, advanced nephrocalcinosis, hyposthenuria and progressive renal failure. The mode of inheritance is autosomal recessive. A primary defect in the reabsorption of magnesium in the medullary thick ascending limb of the loop of Henle (mTAL) has been proposed to be essential in FHHNC pathophysiology. To identify the underlying genetic defect we performed linkage analysis in eight families, including three with consanguineous marriages. We found linkage to microsatellite markers on chromosome 3q27 with a maximum two-point lod score (Zmax) of 5.208 for D3S3530 without evidence for genetic heterogeneity. Haplotype analysis revealed crucial recombination events reducing the critical interval to 6.6cM. Recently, mutations in the gene PCLN-1, mapping to 3q27 and coding for paracellin-1, were identified by Simon et al (1999) as the underlying genetic defect in FHHNC. Paracellin-1 represents a renal tight junction protein predominantly expressed in the TAL. Mutational analysis in our patient cohort revealed eight different mutations in the PCLN-1 gene, within six novel mutations. In seven of 13 mutant alleles we detected a Leu151 substitution without evidence for a founder effect. Leu151 is a residue of the first extracellular loop of paracellin-1, the part of the protein expected to bridge the intercellular space and to be important for paracellular conductance. This study confirms the implication of paracellin-1 defects in FHHNC and points to a predominant role of this protein in the paracellular reabsorption of divalent cations in the TAL.  (+info)

Growth and metabolic disturbances in a patient with total parenteral nutrition: a case of hypercalciuric hypercalcemia. (8/173)

Hypercalciuria is a common side effect during total parenteral nutrition (TPN). We report a patient with long-term TPN, who demonstrated hypercalciuria, hypercalcemia and growth retardation. The patient is a six-year-old Japanese girl with Hirschsprung disease (jejunal agangliosis). Jejunostomy was performed at one-month old and since then her nutrition has depended mostly on TPN. When she was 3 years old, continuous TPN was switched to cyclic TPN (on TPN for 11 hrs and off TPN for 13 hrs). The urinary calcium level has been elevated (Ca/Cre ratio, 1.0) since 3 months of age, whereas serum calcium levels stayed within normal range for a while. The serum calcium levels started to elevate to 12 to approximately 13 mg/dl when she was 3 years and 8 months old. She showed growth retardation (height SD score was -4.2SD when she was 5 years and 8 months old) and deteriorated renal tubular function with renal glycosuria, elevated beta 2-microglobulin (beta2-MG) and N-acetyl-beta-D-glucosaminidase. She was referred to our division for the investigation and treatment of growth disturbance and Ca metabolism. Her bone age was delayed (BA/CA 0.62) and serum IGF-I level was decreased but her GH response to provocation test was normal. Bilateral nephrocalcinosis was revealed by renal echogram and CT scan. By reducing calcium content in TPN solution, the serum and urinary calcium levels could be maintained within normal range and her renal function and growth velocity was improved.  (+info)

Nephrocalcinosis is a medical condition characterized by the deposition of calcium salts in the renal parenchyma, specifically within the tubular epithelial cells and interstitium of the kidneys. This process can lead to chronic inflammation, tissue damage, and ultimately impaired renal function if left untreated.

The condition is often associated with metabolic disorders such as hyperparathyroidism, distal renal tubular acidosis, or hyperoxaluria; medications like loop diuretics, corticosteroids, or calcineurin inhibitors; and chronic kidney diseases. The diagnosis of nephrocalcinosis is typically made through imaging studies such as ultrasound, CT scan, or X-ray. Treatment usually involves addressing the underlying cause, modifying dietary habits, and administering medications to control calcium levels in the body.

Hypercalciuria is a medical condition characterized by an excessive amount of calcium in the urine. It can occur when the body absorbs too much calcium from food, or when the bones release more calcium than usual. In some cases, it may be caused by certain medications, kidney disorders, or genetic factors.

Hypercalciuria can increase the risk of developing kidney stones and other kidney problems. It is often diagnosed through a 24-hour urine collection test that measures the amount of calcium in the urine. Treatment may include changes in diet, increased fluid intake, and medications to help reduce the amount of calcium in the urine.

Inborn errors of renal tubular transport refer to genetic disorders that affect the normal functioning of the kidney tubules. The kidney tubules are responsible for the reabsorption and secretion of various substances, including electrolytes and nutrients, as urine is formed. Inherited defects in the proteins that mediate these transport processes can lead to abnormal levels of these substances in the body and may result in a variety of clinical symptoms.

These disorders can affect different parts of the renal tubule, including the proximal tubule, loop of Henle, distal tubule, and collecting duct. Depending on the specific transporter affected, inborn errors of renal tubular transport can present with a range of clinical manifestations, such as electrolyte imbalances, acid-base disorders, growth retardation, kidney stones, nephrocalcinosis, or even kidney failure.

Examples of inborn errors of renal tubular transport include:

1. Distal renal tubular acidosis (dRTA): A genetic disorder that affects the ability of the distal tubule to acidify urine, leading to metabolic acidosis, hypokalemia, and nephrocalcinosis.
2. Bartter syndrome: A group of autosomal recessive disorders characterized by impaired sodium reabsorption in the loop of Henle, resulting in hypokalemia, metabolic alkalosis, and hyperreninemic hyperaldosteronism.
3. Gitelman syndrome: An autosomal recessive disorder caused by a defect in the thiazide-sensitive sodium chloride cotransporter in the distal tubule, leading to hypokalemia, metabolic alkalosis, and hypocalciuria.
4. Liddle syndrome: An autosomal dominant disorder characterized by increased sodium reabsorption in the collecting duct due to a gain-of-function mutation in the epithelial sodium channel (ENaC), resulting in hypertension, hypokalemia, and metabolic alkalosis.
5. Dent disease: An X-linked recessive disorder caused by mutations in the CLCN5 gene, which encodes a chloride channel in the proximal tubule, leading to low molecular weight proteinuria, hypercalciuria, and nephrolithiasis.
6. Familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC): An autosomal recessive disorder caused by mutations in the CLCN5 or CLDN16 genes, which encode chloride channels in the thick ascending limb of Henle's loop, resulting in hypomagnesemia, hypercalciuria, and nephrocalcinosis.

Claudins are a group of proteins that play a crucial role in the formation and function of tight junctions, which are specialized structures found in the cell membranes of epithelial and endothelial cells. Tight junctions serve as barriers to regulate the paracellular movement of ions, solutes, and water between cells, and claudins are one of the major components that contribute to their selective permeability.

There are over 20 different types of claudins identified in various tissues throughout the body, with each type having a unique structure and function. Claudins can form homotypic or heterotypic interactions with other claudin molecules, allowing for the formation of tight junction strands with varying pore sizes and charge selectivity. This diversity in claudin composition enables the regulation of paracellular transport across different tissues, such as the blood-brain barrier, intestinal epithelium, and renal tubules.

Mutations or dysregulation of claudins have been implicated in several diseases, including cancer, inflammatory bowel disease, and neurological disorders. For example, altered expression levels of specific claudins can contribute to the development of drug resistance in certain types of cancer cells, making them more difficult to treat. Additionally, changes in claudin composition or distribution can disrupt tight junction function, leading to increased permeability and the onset of various pathological conditions.

Hyperoxaluria is a medical condition characterized by an excessive excretion of oxalate in the urine. Oxalate is a naturally occurring substance found in some foods and can also be produced by the body. When oxalate combines with calcium in the urine, it can form kidney stones or calcium oxalate deposits in the kidneys and other tissues, leading to kidney damage or systemic oxalosis. There are three types of hyperoxaluria: primary, secondary, and enteric. Primary hyperoxaluria is caused by genetic defects that affect the body's ability to regulate oxalate production, while secondary hyperoxaluria results from increased dietary intake or absorption of oxalate, or from other medical conditions. Enteric hyperoxaluria occurs in individuals with malabsorption syndromes, such as inflammatory bowel disease or after gastric bypass surgery, where excessive amounts of oxalate are absorbed from the gut into the bloodstream and excreted in the urine.

Medullary sponge kidney (MSK) is a congenital kidney disorder characterized by abnormal dilations of the collecting ducts within the medulla of one or both kidneys. These dilations give the appearance of a "sponge-like" structure, hence the name of the condition.

In MSK, the affected collecting ducts become filled with small cysts or sacs that can trap calcium and other minerals, leading to the formation of recurring kidney stones and chronic kidney disease in some cases. The disorder can also cause urinary tract infections (UTIs) and hematuria (blood in the urine).

MSK is usually asymptomatic and often discovered incidentally during imaging studies performed for other reasons. However, when symptoms do occur, they may include recurrent kidney stones, flank pain, UTIs, or hematuria. The exact cause of MSK remains unclear, but it appears to have a genetic component, as it can be associated with certain inherited syndromes such as Tuberous Sclerosis Complex and Ehlers-Danlos syndrome.

MSK is typically managed through preventative measures aimed at reducing the risk of kidney stone formation, such as increasing fluid intake, maintaining a healthy diet, and taking medications to lower urinary calcium levels if necessary. In some cases, surgery may be required to remove large or recurrent stones or to treat complications associated with the disorder.

Renal tubular acidosis (RTA) is a medical condition that occurs when the kidneys are unable to properly excrete acid into the urine, leading to an accumulation of acid in the bloodstream. This results in a state of metabolic acidosis.

There are several types of RTA, but renal tubular acidosis type 1 (also known as distal RTA) is characterized by a defect in the ability of the distal tubules to acidify the urine, leading to an inability to lower the pH of the urine below 5.5, even in the face of metabolic acidosis. This results in a persistently alkaline urine, which can lead to calcium phosphate stones and bone demineralization.

Type 1 RTA is often caused by inherited genetic defects, but it can also be acquired due to various kidney diseases, drugs, or autoimmune disorders. Symptoms of type 1 RTA may include fatigue, weakness, muscle cramps, decreased appetite, and vomiting. Treatment typically involves alkali therapy to correct the acidosis and prevent complications.

Kidney calculi, also known as kidney stones, are hard deposits made of minerals and salts that form inside your kidneys. They can range in size from a grain of sand to a golf ball. When they're small enough, they can be passed through your urine without causing too much discomfort. However, larger stones may block the flow of urine, causing severe pain and potentially leading to serious complications such as urinary tract infections or kidney damage if left untreated.

The formation of kidney calculi is often associated with factors like dehydration, high levels of certain minerals in your urine, family history, obesity, and certain medical conditions such as gout or inflammatory bowel disease. Symptoms of kidney stones typically include severe pain in the back, side, lower abdomen, or groin; nausea and vomiting; fever and chills if an infection is present; and blood in the urine. Treatment options depend on the size and location of the stone but may include medications to help pass the stone, shock wave lithotripsy to break up the stone, or surgical removal of the stone in severe cases.

Familial Hypophosphatemia is a genetic disorder characterized by low levels of phosphate in the blood (hypophosphatemia) due to impaired absorption of phosphates in the gut. This condition results from mutations in the SLC34A3 gene, which provides instructions for making a protein called NaPi-IIc, responsible for reabsorbing phosphates from the filtrate in the kidney tubules back into the bloodstream.

In familial hypophosphatemia, the impaired function of NaPi-IIc leads to excessive loss of phosphate through urine, resulting in hypophosphatemia. This condition can cause rickets (a softening and weakening of bones) in children and osteomalacia (softening of bones) in adults. Symptoms may include bowed legs, bone pain, muscle weakness, and short stature.

Familial Hypophosphatemia is inherited as an autosomal recessive trait, meaning that an individual must inherit two copies of the mutated gene (one from each parent) to develop the condition.

Bartter syndrome is a rare genetic disorder that affects the kidneys' ability to reabsorb sodium and chloride, leading to an imbalance of electrolytes in the body. This condition is characterized by hypokalemia (low potassium levels), metabolic alkalosis (high pH levels in the blood), and normal or low blood pressure. It can also result in increased urine production, excessive thirst, and growth retardation in children. There are two major types of Bartter syndrome, based on the genes affected: type I caused by mutations in the SLC12A1 gene, and type II caused by mutations in the KCNJ1 gene. Type III is caused by mutations in the CLCNKB gene, while type IV is caused by mutations in the BSND or CLCNKB genes. Treatment typically involves supplementation of electrolytes, such as potassium and magnesium, as well as nonsteroidal anti-inflammatory drugs (NSAIDs) to help reduce sodium loss in the urine.

Primary hyperoxaluria is a rare genetic disorder characterized by overproduction of oxalate in the body due to mutations in specific enzymes involved in oxalate metabolism. There are three types of primary hyperoxaluria (PH1, PH2, and PH3), with PH1 being the most common and severe form.

In primary hyperoxaluria type 1 (PH1), there is a deficiency or dysfunction in the enzyme alanine-glyoxylate aminotransferase (AGT), which leads to an accumulation of glyoxylate. Glyoxylate is then converted to oxalate, resulting in increased oxalate production. Oxalate is a compound that naturally occurs in the body but is primarily excreted through the kidneys. When there is an overproduction of oxalate, it can lead to the formation of calcium oxalate crystals in various tissues, including the kidneys. This can cause recurrent kidney stones, nephrocalcinosis (calcium deposits in the kidneys), and eventually chronic kidney disease or end-stage renal failure.

Primary hyperoxaluria type 2 (PH2) is caused by a deficiency or dysfunction in the enzyme glyoxylate reductase/hydroxypyruvate reductase (GRHPR), leading to an accumulation of glyoxylate, which is subsequently converted to oxalate. PH2 has a milder clinical presentation compared to PH1.

Primary hyperoxaluria type 3 (PH3) is a rare form caused by mutations in the gene HOGA1, which encodes for 4-hydroxy-2-oxoglutarate aldolase. This enzyme deficiency results in an increase in glyoxylate and, subsequently, oxalate production.

Early diagnosis and management of primary hyperoxaluria are crucial to prevent or slow down the progression of kidney damage. Treatment options include increased fluid intake, medications to reduce stone formation (such as potassium citrate), and in some cases, liver-kidney transplantation.

Nephrolithiasis is a medical term that refers to the presence of stones or calculi in the kidney. These stones can form anywhere in the urinary tract, including the kidneys, ureters, bladder, and urethra. Nephrolithiasis is also commonly known as kidney stones.

Kidney stones are hard deposits made up of minerals and salts that crystallize in the urine. They can vary in size from tiny sand-like particles to larger pebble or even golf ball-sized masses. Kidney stones can cause pain, bleeding, and infection if they block the flow of urine through the urinary tract.

The formation of kidney stones is often associated with a variety of factors such as dehydration, high levels of calcium, oxalate, or uric acid in the urine, family history, obesity, and certain medical conditions like gout or inflammatory bowel disease. Treatment for nephrolithiasis depends on the size and location of the stone, as well as the severity of symptoms. Small stones may pass spontaneously with increased fluid intake, while larger stones may require medication, shock wave lithotripsy, or surgical removal.

Magnesium deficiency, also known as hypomagnesemia, is a condition characterized by low levels of magnesium in the blood. Magnesium is an essential mineral that plays a crucial role in many bodily functions, including muscle and nerve function, heart rhythm, bone strength, and immune system regulation.

Hypomagnesemia can occur due to various factors, such as poor dietary intake, malabsorption syndromes, chronic alcoholism, diabetes, certain medications (such as diuretics), and excessive sweating or urination. Symptoms of magnesium deficiency may include muscle cramps, tremors, weakness, heart rhythm abnormalities, seizures, and mental status changes.

It is important to note that mild magnesium deficiency may not cause any symptoms, and the diagnosis typically requires blood tests to measure magnesium levels. Treatment for hypomagnesemia usually involves oral or intravenous magnesium supplementation, along with addressing the underlying causes of the deficiency.

Phosphorus is an essential mineral that is required by every cell in the body for normal functioning. It is a key component of several important biomolecules, including adenosine triphosphate (ATP), which is the primary source of energy for cells, and deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), which are the genetic materials in cells.

Phosphorus is also a major constituent of bones and teeth, where it combines with calcium to provide strength and structure. In addition, phosphorus plays a critical role in various metabolic processes, including energy production, nerve impulse transmission, and pH regulation.

The medical definition of phosphorus refers to the chemical element with the atomic number 15 and the symbol P. It is a highly reactive non-metal that exists in several forms, including white phosphorus, red phosphorus, and black phosphorus. In the body, phosphorus is primarily found in the form of organic compounds, such as phospholipids, phosphoproteins, and nucleic acids.

Abnormal levels of phosphorus in the body can lead to various health problems. For example, high levels of phosphorus (hyperphosphatemia) can occur in patients with kidney disease or those who consume large amounts of phosphorus-rich foods, and can contribute to the development of calcification of soft tissues and cardiovascular disease. On the other hand, low levels of phosphorus (hypophosphatemia) can occur in patients with malnutrition, vitamin D deficiency, or alcoholism, and can lead to muscle weakness, bone pain, and an increased risk of infection.

Amelogenesis Imperfecta is a group of inherited dental disorders that affect the structure and appearance of tooth enamel. It is caused by mutations in various genes involved in the development and formation of enamel. The condition can be characterized by small, discolored, and poorly formed teeth that are prone to rapid wear, decay, and sensitivity. There are several types of Amelogenesis Imperfecta, which vary in their severity and the specific symptoms they present. Treatment typically focuses on managing the symptoms and improving the appearance and function of the teeth through restorative dental procedures.

Calcium oxalate is a chemical compound with the formula CaC2O4. It is the most common type of stone found in kidneys, also known as kidney stones. Calcium oxalate forms when there is too much calcium or oxalate in the urine. This can occur due to various reasons such as dietary habits, dehydration, medical conditions like hyperparathyroidism, or genetic factors.

Calcium oxalate stones are hard and crystalline and can cause severe pain during urination or while passing through the urinary tract. They may also lead to other symptoms like blood in the urine, nausea, vomiting, or fever. Prevention strategies for calcium oxalate stones include staying hydrated, following a balanced diet, and taking prescribed medications to control the levels of calcium and oxalate in the body.

Fanconi syndrome is a medical condition that affects the proximal tubules of the kidneys. These tubules are responsible for reabsorbing various substances, such as glucose, amino acids, and electrolytes, back into the bloodstream after they have been filtered through the kidneys.

In Fanconi syndrome, there is a defect in the reabsorption process, causing these substances to be lost in the urine instead. This can lead to a variety of symptoms, including:

* Polyuria (excessive urination)
* Polydipsia (excessive thirst)
* Dehydration
* Metabolic acidosis (an imbalance of acid and base in the body)
* Hypokalemia (low potassium levels)
* Hypophosphatemia (low phosphate levels)
* Vitamin D deficiency
* Rickets (softening and weakening of bones in children) or osteomalacia (softening of bones in adults)

Fanconi syndrome can be caused by a variety of underlying conditions, including genetic disorders, kidney diseases, drug toxicity, and heavy metal poisoning. Treatment typically involves addressing the underlying cause, as well as managing symptoms such as electrolyte imbalances and acid-base disturbances.

Phosphates, in a medical context, refer to the salts or esters of phosphoric acid. Phosphates play crucial roles in various biological processes within the human body. They are essential components of bones and teeth, where they combine with calcium to form hydroxyapatite crystals. Phosphates also participate in energy transfer reactions as phosphate groups attached to adenosine diphosphate (ADP) and adenosine triphosphate (ATP). Additionally, they contribute to buffer systems that help maintain normal pH levels in the body.

Abnormal levels of phosphates in the blood can indicate certain medical conditions. High phosphate levels (hyperphosphatemia) may be associated with kidney dysfunction, hyperparathyroidism, or excessive intake of phosphate-containing products. Low phosphate levels (hypophosphatemia) might result from malnutrition, vitamin D deficiency, or certain diseases affecting the small intestine or kidneys. Both hypophosphatemia and hyperphosphatemia can have significant impacts on various organ systems and may require medical intervention.

Urolithiasis is the formation of stones (calculi) in the urinary system, which includes the kidneys, ureters, bladder, and urethra. These stones can be composed of various substances such as calcium oxalate, calcium phosphate, uric acid, or struvite. The presence of urolithiasis can cause symptoms like severe pain in the back or side, nausea, vomiting, fever, and blood in the urine. The condition can be managed with medications, increased fluid intake, and in some cases, surgical intervention may be required to remove the stones.

A kidney, in medical terms, is one of two bean-shaped organs located in the lower back region of the body. They are essential for maintaining homeostasis within the body by performing several crucial functions such as:

1. Regulation of water and electrolyte balance: Kidneys help regulate the amount of water and various electrolytes like sodium, potassium, and calcium in the bloodstream to maintain a stable internal environment.

2. Excretion of waste products: They filter waste products from the blood, including urea (a byproduct of protein metabolism), creatinine (a breakdown product of muscle tissue), and other harmful substances that result from normal cellular functions or external sources like medications and toxins.

3. Endocrine function: Kidneys produce several hormones with important roles in the body, such as erythropoietin (stimulates red blood cell production), renin (regulates blood pressure), and calcitriol (activated form of vitamin D that helps regulate calcium homeostasis).

4. pH balance regulation: Kidneys maintain the proper acid-base balance in the body by excreting either hydrogen ions or bicarbonate ions, depending on whether the blood is too acidic or too alkaline.

5. Blood pressure control: The kidneys play a significant role in regulating blood pressure through the renin-angiotensin-aldosterone system (RAAS), which constricts blood vessels and promotes sodium and water retention to increase blood volume and, consequently, blood pressure.

Anatomically, each kidney is approximately 10-12 cm long, 5-7 cm wide, and 3 cm thick, with a weight of about 120-170 grams. They are surrounded by a protective layer of fat and connected to the urinary system through the renal pelvis, ureters, bladder, and urethra.

Gitelman Syndrome is a genetic disorder that affects the electrolyte and fluid balance in the body. It is characterized by low levels of potassium, magnesium, and chloride in the blood due to defects in the function of the distal convoluted tubule in the kidney. This results in increased urinary excretion of these ions.

The condition is caused by mutations in the SLC12A3 gene, which provides instructions for making a protein called thiazide-sensitive sodium chloride cotransporter (NCC). The NCC protein is responsible for reabsorbing sodium and chloride ions from the urine back into the bloodstream. In Gitelman Syndrome, the mutations in the SLC12A3 gene lead to reduced function of the NCC protein, resulting in increased excretion of sodium, chloride, potassium, and magnesium in the urine.

Symptoms of Gitelman Syndrome may include muscle weakness, cramps, spasms, fatigue, salt cravings, thirst, and decreased appetite. The condition is usually diagnosed in childhood or adolescence but can also present in adulthood. Treatment typically involves supplementation with potassium and magnesium to correct the electrolyte imbalances. In some cases, a medication called indapamide may be used to increase sodium reabsorption in the kidney and reduce potassium excretion.

Water-electrolyte imbalance refers to a disturbance in the balance of water and electrolytes (such as sodium, potassium, chloride, and bicarbonate) in the body. This imbalance can occur when there is an excess or deficiency of water or electrolytes in the body, leading to altered concentrations in the blood and other bodily fluids.

Such imbalances can result from various medical conditions, including kidney disease, heart failure, liver cirrhosis, severe dehydration, burns, excessive sweating, vomiting, diarrhea, and certain medications. Symptoms of water-electrolyte imbalance may include weakness, fatigue, muscle cramps, seizures, confusion, and in severe cases, coma or even death. Treatment typically involves addressing the underlying cause and correcting the electrolyte and fluid levels through appropriate medical interventions.

Oxalates, also known as oxalic acid or oxalate salts, are organic compounds that contain the functional group called oxalate. Oxalates are naturally occurring substances found in various foods such as spinach, rhubarb, nuts, and seeds. They can also be produced by the body as a result of metabolism.

In the body, oxalates can bind with calcium and other minerals to form crystals, which can accumulate in various tissues and organs, including the kidneys. This can lead to the formation of kidney stones, which are a common health problem associated with high oxalate intake or increased oxalate production in the body.

It is important for individuals with a history of kidney stones or other kidney problems to monitor their oxalate intake and limit consumption of high-oxalate foods. Additionally, certain medical conditions such as hyperoxaluria, a rare genetic disorder that causes increased oxalate production in the body, may require medical treatment to reduce oxalate levels and prevent complications.

Familial Hypophosphatemic Rickets (FHR) is a genetic disorder characterized by impaired reabsorption of phosphate in the kidneys, leading to low levels of phosphate in the blood (hypophosphatemia). This condition results in defective mineralization of bones and teeth, causing rickets in children and osteomalacia in adults.

FHR is typically caused by mutations in the PHEX gene, which encodes a protein that helps regulate phosphate levels in the body. In FHR, the mutation leads to an overproduction of a hormone called fibroblast growth factor 23 (FGF23), which increases phosphate excretion in the urine and decreases the activation of vitamin D, further contributing to hypophosphatemia.

Symptoms of FHR may include bowing of the legs, bone pain, muscle weakness, short stature, dental abnormalities, and skeletal deformities. Treatment typically involves oral phosphate supplements and active forms of vitamin D to correct the hypophosphatemia and improve bone mineralization. Regular monitoring of blood phosphate levels, kidney function, and bone health is essential for effective management of this condition.

Dietary Phosphorus is a mineral that is an essential nutrient for human health. It is required for the growth, maintenance, and repair of body tissues, including bones and teeth. Phosphorus is also necessary for the production of energy, the formation of DNA and RNA, and the regulation of various physiological processes.

In the diet, phosphorus is primarily found in protein-containing foods such as meat, poultry, fish, dairy products, legumes, and nuts. It can also be found in processed foods that contain additives such as phosphoric acid, which is used to enhance flavor or as a preservative.

The recommended daily intake of phosphorus for adults is 700 milligrams (mg) per day. However, it's important to note that excessive intake of phosphorus, particularly from supplements and fortified foods, can lead to health problems such as kidney damage and calcification of soft tissues. Therefore, it's recommended to obtain phosphorus primarily from whole foods rather than supplements.

Sodium-phosphate cotransporter proteins, type IIc (NPTIIc), are a subtype of sodium-dependent phosphate transporters that play a crucial role in the regulation of phosphate homeostasis within the body. They are located primarily in the kidney's proximal tubule cells and intestinal epithelial cells.

NPTIIc proteins facilitate the active transport of inorganic phosphate (Pi) ions across the cell membrane, in conjunction with sodium ions (Na+). This symport mechanism allows for the movement of Pi against its concentration gradient, from areas of low concentration to high concentration. The energy required for this process is derived from the electrochemical gradient of sodium ions.

These transporters are essential for maintaining normal phosphate levels in the body, as they help reabsorb a significant portion of filtered phosphate in the kidneys and absorb dietary phosphate in the intestines. Dysregulation of NPTIIc proteins can lead to various disorders related to phosphate homeostasis, such as hypophosphatemia (low serum phosphate levels) or hyperphosphatemia (high serum phosphate levels), which can have detrimental effects on bone health, mineral metabolism, and overall body function.

Calcium metabolism disorders refer to a group of medical conditions that affect the body's ability to properly regulate the levels of calcium in the blood and tissues. Calcium is an essential mineral that plays a critical role in many bodily functions, including bone health, muscle contraction, nerve function, and blood clotting.

There are several types of calcium metabolism disorders, including:

1. Hypocalcemia: This is a condition characterized by low levels of calcium in the blood. It can be caused by various factors such as vitamin D deficiency, hypoparathyroidism, and certain medications. Symptoms may include muscle cramps, spasms, and tingling sensations in the fingers and toes.
2. Hypercalcemia: This is a condition characterized by high levels of calcium in the blood. It can be caused by various factors such as hyperparathyroidism, cancer, and certain medications. Symptoms may include fatigue, weakness, confusion, and kidney stones.
3. Osteoporosis: This is a condition characterized by weak and brittle bones due to low calcium levels in the bones. It can be caused by various factors such as aging, menopause, vitamin D deficiency, and certain medications. Symptoms may include bone fractures and loss of height.
4. Paget's disease: This is a condition characterized by abnormal bone growth and deformities due to disordered calcium metabolism. It can be caused by various factors such as genetics, age, and certain medications. Symptoms may include bone pain, fractures, and deformities.

Treatment for calcium metabolism disorders depends on the underlying cause of the condition. It may involve supplements, medication, dietary changes, or surgery. Proper diagnosis and management are essential to prevent complications such as kidney stones, bone fractures, and neurological damage.

Hypoparathyroidism is a medical condition characterized by decreased levels or insufficient function of parathyroid hormone (PTH), which is produced and released by the parathyroid glands. These glands are located in the neck, near the thyroid gland, and play a crucial role in regulating calcium and phosphorus levels in the body.

In hypoparathyroidism, low PTH levels result in decreased absorption of calcium from the gut, increased excretion of calcium through the kidneys, and impaired regulation of bone metabolism. This leads to low serum calcium levels (hypocalcemia) and high serum phosphorus levels (hyperphosphatemia).

Symptoms of hypoparathyroidism can include muscle cramps, spasms, or tetany (involuntary muscle contractions), numbness or tingling sensations in the fingers, toes, and around the mouth, fatigue, weakness, anxiety, cognitive impairment, and in severe cases, seizures. Hypoparathyroidism can be caused by various factors, including surgical removal or damage to the parathyroid glands, autoimmune disorders, radiation therapy, genetic defects, or low magnesium levels. Treatment typically involves calcium and vitamin D supplementation to maintain normal serum calcium levels and alleviate symptoms. In some cases, recombinant PTH (Natpara) may be prescribed as well.

The kidney medulla is the inner portion of the renal pyramids in the kidney, consisting of multiple conical structures found within the kidney. It is composed of loops of Henle and collecting ducts responsible for concentrating urine by reabsorbing water and producing a hyperosmotic environment. The kidney medulla has a unique blood supply and is divided into an inner and outer zone, with the inner zone having a higher osmolarity than the outer zone. This region of the kidney helps regulate electrolyte and fluid balance in the body.

Calcium is an essential mineral that is vital for various physiological processes in the human body. The medical definition of calcium is as follows:

Calcium (Ca2+) is a crucial cation and the most abundant mineral in the human body, with approximately 99% of it found in bones and teeth. It plays a vital role in maintaining structural integrity, nerve impulse transmission, muscle contraction, hormonal secretion, blood coagulation, and enzyme activation.

Calcium homeostasis is tightly regulated through the interplay of several hormones, including parathyroid hormone (PTH), calcitonin, and vitamin D. Dietary calcium intake, absorption, and excretion are also critical factors in maintaining optimal calcium levels in the body.

Hypocalcemia refers to low serum calcium levels, while hypercalcemia indicates high serum calcium levels. Both conditions can have detrimental effects on various organ systems and require medical intervention to correct.

  • Nephrocalcinosis is closely associated with nephrolithiasis, and patients frequently present with both conditions, however there have been cases where one occurs without the other. (wikipedia.org)
  • Nephrocalcinosis is related to, but not the same as, kidney stones (nephrolithiasis). (medlineplus.gov)
  • Nephrolithiasis and nephrocalcinosis. (medlineplus.gov)
  • A rare X-linked monogenic renal tubular disease, characterized by manifestations of complex proximal tubule dysfunction with low-molecular-weight (LMW) proteinuria, hypercalciuria, nephrolithiasis, nephrocalcinosis, and progressive renal failure. (orpha.net)
  • It is characterized by proximal tubule (PT) dysfunction and LMW proteinuria (100% of cases), associated with hypercalciuria (90-95%), nephrolithiasis (30-50%), nephrocalcinosis (40-50%), and progressive renal failure. (orpha.net)
  • Nocturia, polyuria, and polydipsia from reduced urinary concentrating capacity (i.e. nephrogenic diabetes insipidus) as can be seen in hypercalcemia, medullary nephrocalcinosis of any cause, or in children with Bartter syndrome in whom essential tubular salt reabsorption is compromised. (wikipedia.org)
  • Images show bilateral medullary nephrocalcinosis (early arterial phase). (medscape.com)
  • One patient presented with failure to thrive due to marked hypercalcemia (3.9 mmol/l) and nephrocalcinosis , 2 patients showed medullary nephrocalcinosis on ultrasonography and one patient had gross hematuria and spontaneous passage of a calculus . (bvsalud.org)
  • The annual urinary screening of Japanese children above 3 yr of age has identified a progressive proximal renal tubular disorder characterized by low molecular weight proteinuria, hypercalciuria, and nephrocalcinosis. (ox.ac.uk)
  • Vitamin D poisoning in infants: a preventable cause of hypercalciuria and nephrocalcinosis]. (bvsalud.org)
  • The short time interval between vitamin D administration and onset of symptoms and the subsequent clinical course provide strong evidence that hypercalciuria and nephrocalcinosis were due to vitamin D "stoss" prophylaxis in all four cases. (bvsalud.org)
  • FHHNC = Familial hypomagnesemia with hypercalciuria and nephrocalcinosis. (medscape.com)
  • Nephrocalcinosis is a disorder in which there is too much calcium deposited in the kidneys. (medlineplus.gov)
  • Nephrocalcinosis is a condition in which calcium levels in the kidneys are increased. (medscape.com)
  • Nephrocalcinosis means kidneys contain many calcium deposits. (uchicago.edu)
  • As a result Albright coined the word nephrocalcinosis to describe the scarred, contracted kidneys of patients whose primary hyperparathyroidism had caused kidney disease. (uchicago.edu)
  • Excess oxalate production can result in the accumulation of calcium oxalate crystals in the kidneys and urinary tract, which can lead to painful and recurring kidney stones , nephrocalcinosis, kidney failure , and systemic organ dysfunction. (medicinenet.com)
  • Adult patients with RTA are often asymptomatic but may present with muscular weakness related to associated hypokalemia, nephrocalcinosis, or recurrent renal stones. (bmj.com)
  • Distal renal tubular acidosis (RTA) was diagnosed on the basis of the patient's presentation of profound weakness, history of renal colic, ECG findings consistent with severe hypokalemia , renal ultrasound showing nephrocalcinosis , and arterial blood gas analysis showing profound metabolic acidosis . (medscape.com)
  • Urinary tract obstruction, such as a narrowing of the urinary tract (stricture), tumors, kidney stones, nephrocalcinosis or enlarged prostate with subsequent acute bilateral obstructive uropathy. (health.am)
  • Later symptoms related to nephrocalcinosis may be associated with long-term (chronic) kidney failure . (medlineplus.gov)
  • Microscopic nephrocalcinosis in chronic kidney disease patients. (nih.gov)
  • [ 1 ] The most feared chronic complication of hypoparathyroidism treatment is renal toxicity, manifesting as kidney stone or nephrocalcinosis, followed by renal insufficiency. (medscape.com)
  • Nephrocalcinosis, once known as Albright's calcinosis after Fuller Albright, is a term originally used to describe the deposition of poorly soluble calcium salts in the renal parenchyma due to hyperparathyroidism. (wikipedia.org)
  • In conjunction with nephrocalcinosis, hypercalcaemia and hypercalciuria the following can occur: Primary hyperparathyroidism: Nephrocalcinosis is one of the most common symptoms of primary hyperparathyroidism. (wikipedia.org)
  • Nephrocalcinosis was a termed coined by Albright in 1934 to describe the deposition of calcium salts in the renal parenchyma in hyperparathyroidism. (indianradiology.com)
  • Microscopic nephrocalcinosis and hypercalciuria in nephrotic syndrome. (nih.gov)
  • Microscopic nephrocalcinosis in cystic fibrosis. (nih.gov)
  • Nephrocalcinosis is connected with conditions that cause hypercalcaemia, hyperphosphatemia, and the increased excretion of calcium, phosphate, and/or oxalate in the urine. (wikipedia.org)
  • A high urine pH can lead to nephrocalcinosis but only if it is accompanied by hypercalciuria and hypocitraturia, since having a normal urinary citrate usually inhibits the crystallization of calcium. (wikipedia.org)
  • Any disorder that leads to high levels of calcium in the blood or urine may lead to nephrocalcinosis. (medlineplus.gov)
  • Nephrocalcinosis may be discovered when symptoms of renal insufficiency , kidney failure , obstructive uropathy, or urinary tract stones develop. (medlineplus.gov)
  • The term nephrocalcinosis is used to describe the deposition of both calcium oxalate and calcium phosphate. (wikipedia.org)
  • That review begins with a definition: 'Strictly, the term 'nephrocalcinosis' refers to the generalized deposition of calcium oxalate (CaOx) or calcium phosphate (CaPi) in the kidney. (uchicago.edu)
  • Sarcoidosis: Nephrocalcinosis is one of the most common symptoms. (wikipedia.org)
  • Most of the time, there are no early symptoms of nephrocalcinosis beyond those of the condition causing the problem. (medlineplus.gov)
  • Also call if you develop symptoms of nephrocalcinosis. (medlineplus.gov)
  • Nephrocalcinosis (NC) refers to diffuse, fine, renal parenchymal calcification, as assessed by radiology or ultrasonography. (biomedcentral.com)
  • Diffuse nephrocalcinosis and idiopathic renal hypercalciuria. (bmj.com)
  • Idiopathic low molecular weight proteinuria associated with hypercalciuric nephrocalcinosis in Japanese children is due to mutations of the renal chloride channel (CLCN5). (ox.ac.uk)
  • Patients are also frequently referred after fortuitous discovery of nephrocalcinosis, renal stones, proteinuria or other biological signs of PT dysfunction, or after family screening. (orpha.net)
  • Vitamin D: This can cause nephrocalcinosis because of vitamin D therapy because it increases the absorption of ingested calcium and bone resorption, resulting in hypercalcaemia and hypercalciuria. (wikipedia.org)
  • Unlike the patients for whom Albright coined nephrocalcinosis, we mainly study patients whose stones arise from no systemic disease at all. (uchicago.edu)
  • So physicians today use the word nephrocalcinosis to describe very different patients than those Albright studied when he made the word up. (uchicago.edu)
  • My findings indicate that this papillary pattern of nephrocalcinosis shares striking similarities to human kidney stone disease. (ku.edu)
  • In this project, it has been shown that although it is possible to identify severe degrees of nephrocalcinosis macroscopically, one should use histology to assess the condition for a more precise diagnosis. (fis-net.com)
  • Nephrocalcinosis , however, persisted in 2 patients and showed a slight progression ultrasonographically in one patient . (bvsalud.org)
  • During its early stages, nephrocalcinosis is visible on x-ray, and appears as a fine granular mottling over the renal outlines. (wikipedia.org)
  • Nephrocalcinosis is a serious welfare challenge in the early life phase of farmed salmon, which can have dramatic consequences for the fish's health and survival. (fis-net.com)
  • Ammenti A, Pelizzoni A, Cecconi M, Molinari PP, Montini G: Nephrocalcinosis in children: a retrospective multi-centre study. (biomedcentral.com)
  • Once the diagnosis is confirmed additional testing is needed to find the underlying cause because the underlying condition may require treatment for reasons independent of nephrocalcinosis. (wikipedia.org)
  • Prompt treatment of disorders that lead to nephrocalcinosis, including RTA, may help prevent it from developing. (medlineplus.gov)
  • When I looked up nephrocalcinosis in PubMed , I found 2686 entries. (uchicago.edu)
  • The term nephrocalcinosis most often applies to a generalized increase in renal calcium content, as opposed to the localized increase observed in calcified renal infarct and caseating granulomas of renal tuberculosis. (medscape.com)
  • My work suggests that proximal delivery of calcium to the loops of Henle is important in the pathogenesis of nephrocalcinosis and kidney stone formation. (ku.edu)
  • In some cases a renal biopsy is done instead if imaging is not enough to confirm nephrocalcinosis. (wikipedia.org)
  • The use of X-rays was tested in a pilot study, and offers interesting possibilities for assessing nephrocalcinosis without having to kill the fish. (fis-net.com)
  • Differences in feed composition used in the various facilities in the mapping study were not correlated with the differences in the proportion of fish with nephrocalcinosis. (fis-net.com)
  • A clear increase in the proportion of fish with nephrocalcinosis supported the observations in the mapping study, which suggested that seawater may be one of the risk factors for the development of nephrocalcinosis. (fis-net.com)

No images available that match "nephrocalcinosis"